Cat. No.: HY-12053A

Copy Link Print Information

Vinorelbine ditartrate

(Synonyms: KW-2307; Nor-5'-anhydrovinblastine ditartrate)

23 Cited Publications

Customer Review

Based on 23 publication(s) in Google Scholar

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC₅₀ of 1.25 nM.

For research use only. We do not sell to patients.

Purity: 99.96%
CAS No.: 125317-39-7
Formula: C₅₃H₆₆N₄O₂₀
Molecular Weight:1079.11

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Vinorelbine ditartrate Chemical Structure

CAS No.: 125317-39-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (23)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC₅₀ of 1.25 nM.

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.009 μM Compound: 1d	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 19499938]
HeLa	IC₅₀	0.009 μM Compound: 1d	Cytotoxicity against human HeLa cells by sulforhodamine B assay Cytotoxicity against human HeLa cells by sulforhodamine B assay	[PMID: 19499938]

In Vitro

Vinorelbine (0.5-5 nM) ditartrate inhibits cell proliferation by 50% (IC₅₀) at concentrations of 1.25 nM. At a concentration of 8 nM, no cells are in anaphase^[1]. Vinorelbine ditartrate time-dependently induces the p53 and p21^WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine ditartrate stimulates reporter genes in a concentration-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 125317-39-7
Appearance Solid
Molecular Weight 1079.11
Formula C₅₃H₆₆N₄O₂₀
Color White to off-white
SMILES

CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@@](C4=C5C(C=CC=C6)=C6N4)(CC(C=C(CC)C7)([H])CN7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Synonyms

KW-2307; Nor-5'-anhydrovinblastine ditartrate
Structure Classification
- Alkaloids
- Alkaloid Dimers
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (23)

All Histological Imaging/StainingRT-PCRIn Vivo Efficacy StudyCell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Cell Mol Immunol

Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]

2023 Jan;20(1):51-64. PMID: 36447031

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Sci Adv

Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. [Abstract]

2023 Jun 2;9(22):eadc9273. PMID: 37256945

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]

CCK-8 assay data showing the sensitivity of NCI-H460-DOT1L-WT/R231Q cells to cisplatin, vinorelbine, and SGC0946. Cells were treated for 72 hours (Cisplatin and Vinorelbine (0.01-100 μM)) or 6 days (SGC0946). IC₅₀ values were calculated using SPSS V 21.0 software.

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]

CDX-bearing mice (n = 7 mice per group) were treated with vehicle [10% dimethyl sulfoxide (DMSO) + 40% polyethylene glycol 300 (PEG300) + 5% Tween 80 + 45% saline, five times per week], Cisplatin (3 mg/kg, twice per week), Vinorelbine (4 mg/kg, twice per week), or SGC0946 (20 mg/kg, five times per week) through intraperitoneal administration. The graphs show the tumor images and weights, with the tumor inhibition rate (TIR%). (TIR%) = (1 − average tumor weight after drug treatment/average tumor weight of vehicle control) × 100%.

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]

Synergistic effect of MAPK inhibition with Cisplatin or Vinorelbine on NCI-H460-DOT1L-R231Q cells after 72 hours of treatment.
Cell Death Dis

PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]

2026 Apr 3;17(1):449. PMID: 41932868
EBioMedicine

Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma. [Abstract]

2021 Aug:70:103510. PMID: 34365093

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2021 Aug:70:103510. [Abstract]

We compared the actual drug response data of the aforementioned S1/S2 specific agents between S1- and S2-like cells and found that S1-like cell lines were more sensitive to TG-101348, while S2-like cell lines (ESCC cancer cell lines) were more sensitive to Vinorelbine (48 h) and ZM-447439.
Microsyst Nanoeng

Double emulsion-pretreated microwell culture for the in vitro production of multicellular spheroids and their in situ analysis. [Abstract]

2021 May 24:7:38. PMID: 34567752
Acta Pharmacol Sin

A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. [Abstract]

2024 Oct;45(10):2174-2185. PMID: 38844788
Biochem Pharmacol

Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. [Abstract]

2020 May;175:113865. PMID: 32142727
Microb Cell Fact

Lactobacillus gasseri LGV03-derived indole-3-lactic acid ameliorates immune response by activating aryl hydrocarbon receptor. [Abstract]

2025 Jan 30;24(1):34. PMID: 39885499

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]

L. gasseri LGV03 inhibits Vinorelbine (200 μg/mL, 96 h)-induced macrophage reduction in zebrafish model Tg (mpeg-EGFP) (right). Number of macrophages in zebrafish after treatment of Vinorelbine and L. gasseri LGV03 (left).

Vinorelbine ditartrate purchased from MedChemExpress. Usage Cited in: Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]

mRNA gene expression of cytokines TNF-α, TNF-β and IFN-α in zebrafish (Vinorelbine, 200 μg/mL, 96 h).
Int J Cancer

Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]

2024 Jul 15;155(2):324-338. PMID: 38533706
Cancers (Basel)

miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs. [Abstract]

2021 Jul 2;13(13):3323. PMID: 34283053
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
Adv Ther

2024 Jul 18.
iScience

Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]

2022 Sep 6;25(10):105081. PMID: 36204272
J Bone Oncol

Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]

2021 Sep 20:30:100391. PMID: 34611509
Transl Lung Cancer Res

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]

2024 Oct 31;13(10):2698-2712. PMID: 39507032
Am J Cancer Res

Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. [Abstract]

2021 Apr 15;11(4):1428-1445. PMID: 33948366
Biochem Biophys Res Commun

Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. [Abstract]

2020 May 21;526(1):154-157. PMID: 32201082
Int J Clin Pract

2026 Apr 25;2026(1):6800480.
Res Sq

2026 Jan 9.
bioRxiv

2026 Jan 9.
bioRxiv

MCL1 may not mediate chemoresistance. [Abstract]

2025 Aug 27:2025.08.22.671824. PMID: 40909578
Res Sq

Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]

2025 May 16:rs.3.rs-6590535. PMID: 40470249

Solvent & Solubility

In Vitro:

DMSO : 175 mg/mL (162.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (92.67 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9267 mL

4.6334 mL

9.2669 mL

5 mM

0.1853 mL

0.9267 mL

1.8534 mL

10 mM

0.0927 mL

0.4633 mL

0.9267 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (46.33 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: Saline

Solubility: 20 mg/mL (18.53 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocol

Animal Administration^[4]

As defined by the study, VRL1 is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL, and given IV over 5 minutes. The intended treatment interval is 7 days for up to 4 treatments. After receiving 4 weekly doses, cats are eligible to continue VRL treatment every 2 weeks.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32. [Content Brief]

[2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73. [Content Brief]

[3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9. [Content Brief]

[4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.9267 mL	4.6334 mL	9.2669 mL	23.1672 mL
	5 mM	0.1853 mL	0.9267 mL	1.8534 mL	4.6334 mL
	10 mM	0.0927 mL	0.4633 mL	0.9267 mL	2.3167 mL
	15 mM	0.0618 mL	0.3089 mL	0.6178 mL	1.5445 mL
	20 mM	0.0463 mL	0.2317 mL	0.4633 mL	1.1584 mL
	25 mM	0.0371 mL	0.1853 mL	0.3707 mL	0.9267 mL
	30 mM	0.0309 mL	0.1544 mL	0.3089 mL	0.7722 mL
	40 mM	0.0232 mL	0.1158 mL	0.2317 mL	0.5792 mL
	50 mM	0.0185 mL	0.0927 mL	0.1853 mL	0.4633 mL
	60 mM	0.0154 mL	0.0772 mL	0.1544 mL	0.3861 mL
	80 mM	0.0116 mL	0.0579 mL	0.1158 mL	0.2896 mL
DMSO	100 mM	0.0093 mL	0.0463 mL	0.0927 mL	0.2317 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Vinorelbine ditartrate

23 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Vinorelbine ditartrate

Cell Cycle/DNA Damage Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Chemotherapy Drug Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Vinorelbine ditartrate

Biological Activity

Chemical Information

Publications (23)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Vinorelbine ditartrate Related Classifications

HY-12053A Related Classifications